| AASLD

Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin‐6 signaling

Read more about Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin‐6 signaling

Nicholas A. Shackel, Geoffrey W. McCaughan, Fiona J. Warner – 28 May 2008

Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C

Read more about Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C

Simone Carotti, Sergio Morini, Stefano Ginanni Corradini, Maria Antonella Burza, Antonio Molinaro, Guido Carpino, Manuela Merli, Adriano De Santis, Andrea Onetti Muda, Massimo Rossi, Adolfo Francesco Attili, Eugenio Gaudio – 28 May 2008 – Activated alpha‐smooth muscle actin (α‐SMA)–positive hepatic stellate cells (HSCs) are pericytes responsible for fibrosis in chronic liver injury. The glial fibrillary acidic protein (GFAP), commonly expressed by astrocytes in the central nervous system, is expressed in vivo in the liver in a subpopulation of quiescent stellate cells.

MicroRNA expression profiling: A molecular tool for defining the phenotype of hepatocellular tumors

Read more about MicroRNA expression profiling: A molecular tool for defining the phenotype of hepatocellular tumors

Chiara Braconi, Tushar Patel – 28 May 2008

A grapefruit a day for patients infected with hepatitis C?

Read more about A grapefruit a day for patients infected with hepatitis C?

Peter N. Morcos, Barbara Brennan, Patrick F. Smith – 28 May 2008

Hepatocellular carcinoma developed on compensated cirrhosis: Resection as a selection tool for liver transplantation

Read more about Hepatocellular carcinoma developed on compensated cirrhosis: Resection as a selection tool for liver transplantation

Olivier Scatton, Stéphane Zalinski, Benoit Terris, Jérémie H. Lefevre, Alessandra Casali, Pierre‐Philippe Massault, Filomena Conti, Yvon Calmus, Olivier Soubrane – 28 May 2008 – The objective of this study was to evaluate the histological profile obtained from primary resection of hepatocellular carcinoma (HCC) as a selection tool for liver transplantation (LT). The natural history of HCC depends on its histological features. The clinical effectiveness of resection as a selection tool for salvage or de principe LT has been previously advocated.

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

Read more about Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

Ming‐Lung Yu, Chia‐Yen Dai, Jee‐Fu Huang, Chang‐Fu Chiu, Yi‐Hsin C. Yang, Nai‐Jen Hou, Li‐Po Lee, Ming‐Yen Hsieh, Zu‐Yau Lin, Shinn‐Cherng Chen, Ming‐Yuh Hsieh, Liang‐Yen Wang, Wen‐Yu Chang, Wan‐Long Chuang – 28 May 2008 – Recommended treatment for hepatitis C virus genotype 1 (HCV‐1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV‐1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks).